Nova Eye Medical’s Innovative Approach to Glaucoma Treatment: A Clinical Study Update

Nova Eye Medical Ltd ((ELXMF)) announced an update on their ongoing clinical study.

Study Overview: Nova Eye Medical Ltd is conducting a clinical study titled ‘Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma.’ The study aims to evaluate the effectiveness of combining cataract surgery with ab-interno canaloplasty versus cataract surgery alone in treating mild to moderate primary open-angle glaucoma. This research is significant as it could improve treatment outcomes for glaucoma patients.

Intervention/Treatment: The study tests two interventions: cataract surgery combined with ab-interno canaloplasty using the iTrack Advance canaloplasty device, and cataract surgery alone. The purpose is to determine if the combined approach offers better results in managing glaucoma.

Study Design: This is a prospective, multicenter, randomized, single-masked clinical trial. Participants are randomly assigned to either the combined surgery group or the cataract surgery-only group. The primary goal is to assess treatment efficacy, with participants being masked to the intervention they receive.

Study Timeline: The study began on September 29, 2022, and is currently recruiting participants. The primary completion date is yet to be determined, with the last update submitted on April 15, 2025. These dates are crucial for tracking the study’s progress and anticipated results.

Market Implications: This study could significantly impact Nova Eye Medical’s stock performance and investor sentiment. Positive results may enhance the company’s market position in the ophthalmology sector, potentially affecting competitors and industry dynamics.

The study is ongoing, with further details available on the ClinicalTrials portal.